Update on the safety and bioequivalence of biosimilars - Focus on enoxaparin

Drug, Healthcare and Patient Safety

Volumn 5, Issue 1, 2013, Pages 133-141

  Jeske, Walter ^a   Walenga, Jeanine M ^a   Hoppensteadt, Debra ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Biosimilar; Generic; Low molecular weight heparin

Indexed keywords

BIOSIMILAR AGENT; ENOXAPARIN; FONDAPARINUX; GENERIC DRUG; HEPARIN; HUMAN GROWTH HORMONE; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTERY THROMBOSIS; BIOEQUIVALENCE; DRUG APPROVAL; DRUG MANUFACTURE; DRUG POTENCY; DRUG PURITY; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOGENICITY; NONHUMAN; PATIENT SAFETY; PHARMACODYNAMICS; PURE RED CELL ANEMIA; RECOMBINANT DNA TECHNOLOGY; REVIEW; SIDE EFFECT; VEIN THROMBOSIS;

EID: 84878973713     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/DHPS.S28813     Document Type: Review

References (76)

1. Walsh G. Biopharmaceutical benchmarks 2010. Nature Biotech. 2010; 28(9):917-924.
2. Kueppers E. Follow on biologics: how to develop a competitive advantage. Bus Dev Licens J. 2010;12:17-18.
3. Biologic drugs set to top 2012 sales. Nat Med. 2012;18(5):636.
4. Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs. 2011;71(12):1527-1536.
5. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11(7):527-540.
6. Erickson BE. Untangling Biosimilars. Chem Eng News. 2010;88(48): 25-27.
7. Drug Price Competition and Patent Term Restoration Act. [Public Law 98-417], 1984.
8. Gottlieb S. Biosimilars: policy, clinical, and regulatory considerations. Am J Health Syst Pharm. 2008;65(14 Suppl 6):S2-S8.
9. Facts about Generic Drugs. http://www.fda.gov/downloads/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/understandinggenericdrugs/ucm305908.PDF
10. Dooren JC. FDA withdraws approval of a generic version of Wellbutrin. Wall Street Journal. October 3, 2012.
11. Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. N Engl J Med. 2011;365(5):385-388.
12. Johnson PE. Implications of biosimilars for the future. Am J Health Syst Pharm. 2008;65(14 Suppl 6):S16-S22.
13. Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res. 2011;3:29-36.
14. Hackbarth GM, Crosson FJ, Miller ME. Report of the Congress: Improving Incentives in the Medicare Program. Washington: Medicare Payment Advisory Commission; 2009.
15. Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120(26):5111-5117.
16. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91(3):405-417.
17. Generics and Biosimilars Initiative [homepage on the Internet]. Biosimilars approved in Europe. GaBI Online; 2013. Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe. Accessed January 24, 2013.
18. Generics and Biosimilars Initiative [homepage on the Internet]. Biosimilars applications under review by EMA. GaBI Online; 2013. Available from: http://gabionline.net/Biosimilars/General/Biosimilars-applications-under-review-by-EMA. Accessed Januray 24, 2013.
19. Sekhon BS, Saluja V. Biosimilars: an overview. Biosimilars. 2011;1(1): 1-11.
20. Deechongkit S, Aoki KH, Park SS, Kerwin BA. Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex. J Pharm Sci. 2006;95(9): 1931-1943.
21. Park S, Patel K, Ko J, et al. Analytical comparisons of erythropoietin products from Korea and Amgen's Epogen® (epoetin alfa) [abstract]. Nephrol Dial Transplant. 2006;21:iv14.
22. Schellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus. 2009;2(Suppl 1):i27-i36.
23. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20 Suppl 6:vi3-vi9.
24. Patient Protection and Affordable Care Act [Public Law 111-148], 2010.
25. www.fda.gov [homepage on the Internet]. FDA issues draft guidance on biosimilar product development. US Food and Drug Administration; 2012. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm291232.htm. Accessed May 6, 2013.
26. www.ema.europa.eu [homepage on the Internet]. European Medicines Agency scientific guidance documents on biosimilar medicines. European Medicines Agency; 2013. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp. Accessed January 23, 2013.
27. Kálmán-Szekeres Z, Olajos M, Ganzler K. Analytical aspects of biosimilarity issues of protein drugs. J Pharm Biomed Anal. 2012;69: 185-195.
28. Zuñiga L, Calvo B. Biosimilars: pharmacovigilance and risk management. Pharmacoepidemiol Drug Saf. 2010;19(7):661-669.
29. Chow SC, Endrenyi L, Lachenbruch PA, Yang LY, Chi E. Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics. Biosimilars. 2011;1:13-26.
30. www.ema.europa.eu. European public access reports. European Medicines Agency; 2013. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit. Accessed April 17, 2013.
31. Sörgel F, Lerch H, Lauber T. Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs. 2010;24(6):347-357.
32. Skrlin A, Radic I, Vuletic M, et al. Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals. 2010;38(5):557-566.
33. Sourgens H, Lefrère F. A systematic review of available clinical evidence - filgrastim compared with lenograstim. Int J Clin Pharmacol Ther. 2011;49(8):510-518.
34. Abraham I, Tharmarajah S, MacDonald K. Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. Expert Opin Drug Saf. 2013;12(2):235-246.
35. Waller CF, Semiglazov VF, Tjulandin S, Bentsion D, Chan S, Challand R. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie. 2010;33(10):504-511.
36. Waller CF, Bronchud M, Mair S, Challand R. Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol. 2010;89(10): 971-978.
37. Stanhope R, Sörgel F, Gravel P, Pannatier Schuetz YB, Zabransky M, Muenzberg M. Bioequivalence studies of omnitrope, the first biosimilar/rhGH follow-on protein: two comparative phase 1 randomized studies and population pharmacokinetic analysis. J Clin Pharmacol. 2010;50(11):1339-1348.
38. Romer T, Peter F, Saenger P, et al. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution. J Endocrinol Invest. 2007;30(7):578-589.
39. Peterkova V, Arslanoglu I, Bolshova-Zubkovskaya E, et al. A randomized, double-blind study to assess the efficacy and safety of valtropin, a biosimilar growth hormone, in children with growth hormone deficiency. Horm Res. 2007;68(6):288-293.
40. Kerkhofs L, Boschetti G, Lugini A, Stanculeanu DL, Palomo AG. Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience. Future Oncol. 2012;8(6):751-756.
41. Haag-Weber M, Vetter A, Thyroff-Friesinger U. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol. 2009;72(5):380-390.
42. Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial. BMC Clin Pharmacol. 2009;9:10.
43. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011;80(1):88-92.
44. Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs. 2013;73(2):117-130.
45. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999;25 Suppl 3: 5-16.
46. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl 3):188S-203S.
47. Casu B, Torri G. Structural characterization of low molecular weight heparins. Semin Thromb Hemost. 1999;25 Suppl 3:17-25.
48. Wolff JJ, Chi L, Linhardt RJ, Amster IJ. Distinguishing glucuronic from iduronic acid in glycosaminoglycan tetrasaccharides by using electron detachment dissociation. Anal Chem. 2007;79(5):2015-2022.
49. Loganathan D, Wang HM, Mallis LM, Linhardt RJ. Structural variation in the antithrombin III binding site region and its occurrence in heparin from different sources. Biochemistry. 1990;29(18):4362-4368.
50. Houiste C, Auguste C, Macrez C, Dereux S, Derouet A, Anger P. Quantitative PCR and disaccharide profiling to characterize the animal origin of low-molecular-weight heparins. Clin Appl Thromb Hemost. 2009;15(1):50-58.
51. Alban S. Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma. Semin Thromb Hemost. 2001;27(5):503-511.
52. Holmer E, Kurachi K, Söderström G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J. 1981;193(2):395-400.
53. Khorana AA, Sahni A, Altland OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol. 2003;23(11):2110-2115.
54. Bray B, Lane DA, Freyssinet JM, Pejler G, Lindahl U. Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin. Biochem J. 1989;262(1):225-232.
55. Fareed J, Hoppensteadt D, Jeske W et al. Low molecular weight heparins: a developmental perspective. Expert Opin Investig Drugs. 1997; 6(6):705-733.
56. Walenga JM, Petitou M, Samama M, Fareed J, Choay J. Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity. Thromb Res. 1988;52(6):553-563.
57. Bianchini P, Liverani L, Mascellani G, Parma B. Heterogeneity of unfractionated heparins studied in connection with species, source, and production processes. Semin Thromb Hemost. 1997;23(1):3-10.
58. Lindahl U, Kusche-Gullberg M, Kjellén L. Regulated diversity of heparan sulfate. J Biol Chem. 1998;273(39):24979-24982.
59. Turnbull J, Powell A, Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol. 2001;11(2):75-82.
60. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999;25 Suppl 3: 5-16.
61. Bianchini P, Mascellani G. Few bicyclic acetals at reducing end of low-molecular-weight heparins: might they restrict specification of pharmacopoeia? Pharmeur Sci Notes. 2005;2005(1):1-3.
62. Fareed J, Jeske W, Hoppensteadt D et al. Are the available low-molecular-weight heparin preparations the same? Semin Thromb Hemost. 1996;22 Supl 1:77-91.
63. Petitou M, Hérault JP, Bernat A, et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature. 1999;398(6726): 417-422.
64. Jeske W, Litinas E, Khan H, Hoppensteadt D, Fareed J. A comparison of the pharmacodynamic behavior of branded and biosimilar enoxaparin in primates. Clin Appl Thromb Hemost. 2012;18(3):294-298.
65. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;103(24):2994-3018.
66. Greinacher A, Althaus K, Krauel K, Selleng S. Heparin-induced thrombocytopenia. Hamostaseologie. 2010;30(1):17-18, 20.
67. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355(8):809-817.
68. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-Induced Thrombocytopenia, 4th ed. New York: Informa Healthcare USA, Inc; 2007:67-116.
69. Horne MK, Hutchison KJ. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol. 1998;58(1):24-30.
70. Horsewood P, Warkentin TE, Hayward CP, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996;95(1):161-167.
71. Blank M, Eldor A, Tavor S, et al. A mouse model for heparin-induced thrombocytopenia. Semin Hematol. 1999;36(1 Suppl 1):12-16.
72. Throckmorton D. FDA response to Citizen Petition, Docket No. FDA-2003-P-0273. Rockville: US Food and Drug Administration; 2010. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM220083.pdf. Accessed May 5, 2013.
73. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight-heparins. London: European Medicines Agency; 2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003927.pdf. Accessed May 5, 2013.
74. Harenberg J, Kakkar A, Bergqvist D, et al. Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost. 2009;7(7): 1222-1225.
75. Kalodiki E, Fareed J, Tapson VF, et al. A consensus conference on complex biologics and low molecular weight heparins. Int Angiol. 2010;29(2):193-196.
76. Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy. 2005;25(7):954-962.